Abstract Details

Title Trends in Outcome and Hospitalization Charges of Pediatric Patients Admitted with Myasthenia Gravis Treated with Intravenous Immunoglobulin in the United States. Data from Kids' Inpatient Database (KID) 1997-2009

Topic Child Neurology/Developmental Neurobiology

Presentation(s) P03 - (-)

Poster/Presentation
Number 006

Objective

Background BACKGROUND: Over the past decade, IGIV have been more extensively used as an alternative to plasmapheresis to treats MG.

Design/Methods DESIGN/METHODS: We determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for pediatric patients hospitalized with MG treated with IGIV from 1997 to 2009 using Kids inpatient Database (KID).

Results RESULTS: From 1997 to 2009, 3.4% to 24% of MG patients were treated with IGIV. There was a steady increase in the number of MG patients treated with IGIV from 1997 (5) to 2009 (76). The average patient age was not significantly different in the study time period, with a minimum of 9±6.48 years in 1997 and a maximum of 13±5 years in 2009 (p=0.36). Female predominance was observed in all time periods. The average length of stay was not significantly different from 1997 to 2009. The minimum average length of stay was 2.63±2.16 days in 2003 and the maximum was 7.27±8.32 days in 1997 (p=0.5). The vast majority of patients were discharged to home in all studied time periods. During the studied time periods there was no death. There was a significant increase in average hospital charges over time: $18,960±17,379 in 1997 and $77,299±102,591 in 2009 (p=0.009). This difference persisted after adjustment for inflation.

Conclusions CONCLUSIONS: There was a steady increase in the number of pediatric MG patients treated with IGIV from 1997 to 2009. There was a significant increase in in-hospital charges of patients admitted for MG from 1997 to 2009, but without any significant variation in average length of stay, death rate, and disposition status.

Authors/Disclosures
Zaid Al-Qudah, MD (Associate Specialist Inc.) PRESENTER	No disclosure on file
Andrew W. Penn, MD (Centre for Stroke Research)	No disclosure on file
Rania A. Elenein, MD (Jefferson Health NJ)	Dr. Elenein has nothing to disclose.
Wenzhuan He, MD (UPMC Susquehanna Neurology)	Dr. He has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��